The AACR remains fully committed to supporting publishing operations throughout this challenging time, while still remaining flexible and supportive of the author, reviewer, and editor communities that we serve. If you have any questions or concerns, please reach out to a member of the AACR publishing staff.
Please visit the COVID-19 & Cancer Resource Center where COVID-related content is freely available.
News from Cancer Discovery
- Three-Drug Regimen Bests Chemo in NSCLC
Tremelimumab plus durvalumab and chemotherapy extend PFS, OS in patients with metastatic disease. - Once Is Enough for WGS in Cancer
Study finds that actionable mutations in metastases rarely change during treatment. - Nongenetic Adaptations Allow Cancer Cells to Proliferate
”Persister” cells may drive relapse, but have potentially exploitable characteristics. - Q&A: Theodore Laetsch on Tumor-Agnostic Therapies
Being biomarker-specific, studying rare patient populations could help the field advance more quickly.
Advertisement
Trending - Altmetric
- Six Month Efficacy and Toxicity Profile of BNT162b2 Vaccine in Cancer Patients with Solid TumorsLast mentioned on Thu Sep 16 2021
- Low Dose Radiotherapy Reverses Tumor Immune Desertification and Resistance to ImmunotherapyLast mentioned on Fri Sep 17 2021
- Mobocertinib (TAK-788): A Targeted Inhibitor of EGFR Exon 20 Insertion Mutants in Non–Small Cell Lung CancerLast mentioned on Thu Sep 16 2021
- Rates and patterns of clonal oncogenic mutations in the normal human brainLast mentioned on Sat Sep 04 2021
- See more
